(CLNN) – Globe Newswire
-
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
-
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
-
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
-
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
-
Clene to Present at the 36th Annual ROTH Conference
-
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
-
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
-
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
-
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
-
Clene Provides Update on ALS Clinical Development Meeting With FDA
-
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
-
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
-
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
-
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
-
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
-
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
-
Clene to Present at Upcoming September Conferences
-
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
-
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
-
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
-
Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
-
Clene Announces Pricing of $40 Million Public Offering
-
Clene Announces Launch of Proposed Public Offering
-
Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
-
Clene to Participate in the Maxim Group Virtual Healthcare Conference
-
Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis
-
Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights
-
ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting
-
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
-
Clene Appoints Neurology Expert to Executive Team
-
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights
-
CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
-
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
-
Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series
-
New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
-
Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System
-
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
-
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
-
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
-
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
-
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
-
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
-
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
-
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
-
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying T
-
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying T
-
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
-
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
-
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
Back to CLNN Stock Lookup
